Eli Lilly and Co. saw its shares rise nearly 7% on Friday after an influential committee within the European Medicines Agency recommended Jaypirca for use in adults with chronic lymphocytic leukemia across all lines of therapy. This development draws market attention as it potentially expands the patient population for the drug in Europe.
Additionally, Thailand’s Depositary Receipt of Eli Lilly issued by KTB, LLY80, rose 11% in the morning session to trade at THB 2.10 per share, tracking the momentum of the referenced stock.
The EMA’s Committee for Medicinal Products for Human Use provided a favorable opinion on Jaypirca, suggesting its approval for CLL patients regardless of whether they have previously received BTK inhibitor treatment. Jaypirca has existing approvals in some countries for select hematological cancers, but this regulatory step could significantly broaden its application in the European Union should the European Commission grant final authorization.
In addition to the progress in Europe, Eli Lilly has submitted clinical data for Jaypirca to the US Food and Drug Administration. A decision from US regulators is anticipated in the latter half of 2026.
If approved for the expanded use, Jaypirca would become a treatment option for CLL patients in Europe at any stage of the disease, with or without prior BTK inhibitor therapy. The European Commission is expected to make a final ruling within the next one to two months.
